201 related articles for article (PubMed ID: 16115927)
21. Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy.
Suekane S; Noguchi M; Nakashima O; Yamada S; Kojiro M; Matsuoka K
Int J Urol; 2007 Aug; 14(8):713-8. PubMed ID: 17681061
[TBL] [Abstract][Full Text] [Related]
22. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
[TBL] [Abstract][Full Text] [Related]
23. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.
Prtilo A; Leach FS; Markwalder R; Kappeler A; Burkhard FC; Cecchini MG; Studer UE; Thalmann GN
J Urol; 2005 Nov; 174(5):1814-8; discussion 1818. PubMed ID: 16217293
[TBL] [Abstract][Full Text] [Related]
24. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer.
Horinaga M; Okita H; Nakashima J; Kanao K; Sakamoto M; Murai M
Urology; 2005 Sep; 66(3):671-5. PubMed ID: 16140113
[TBL] [Abstract][Full Text] [Related]
26. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
[TBL] [Abstract][Full Text] [Related]
27. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001.
Sengupta S; Slezak JM; Blute ML; Leibovich BC; Sebo TJ; Myers RP; Cheville JC; Bergstralh EJ; Zincke H
Cancer; 2006 Jun; 106(12):2630-5. PubMed ID: 16703592
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Perner S; Hofer MD; Kim R; Shah RB; Li H; Möller P; Hautmann RE; Gschwend JE; Kuefer R; Rubin MA
Hum Pathol; 2007 May; 38(5):696-701. PubMed ID: 17320151
[TBL] [Abstract][Full Text] [Related]
29. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
Sim HG; Telesca D; Culp SH; Ellis WJ; Lange PH; True LD; Lin DW
J Urol; 2008 May; 179(5):1775-9. PubMed ID: 18343432
[TBL] [Abstract][Full Text] [Related]
30. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
[TBL] [Abstract][Full Text] [Related]
31. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer.
Ayala G; Tuxhorn JA; Wheeler TM; Frolov A; Scardino PT; Ohori M; Wheeler M; Spitler J; Rowley DR
Clin Cancer Res; 2003 Oct; 9(13):4792-801. PubMed ID: 14581350
[TBL] [Abstract][Full Text] [Related]
32. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
33. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
[TBL] [Abstract][Full Text] [Related]
34. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Kosma VM
Br J Cancer; 1999 May; 80(3-4):477-82. PubMed ID: 10408856
[TBL] [Abstract][Full Text] [Related]
35. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
[TBL] [Abstract][Full Text] [Related]
36. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
37. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
[TBL] [Abstract][Full Text] [Related]
38. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer.
Vis AN; Schröder FH; van der Kwast TH
Eur Urol; 2006 Aug; 50(2):258-65. PubMed ID: 16413660
[TBL] [Abstract][Full Text] [Related]
39. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
Thompson RH; Blute ML; Slezak JM; Bergstralh EJ; Leibovich BC
J Urol; 2007 Aug; 178(2):459-63; discussion 463. PubMed ID: 17561132
[TBL] [Abstract][Full Text] [Related]
40. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
